Compare Crispr Therapeutics AG (CRSP) vs Lemonade Inc (LMND) Price & Performance

CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.

The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.

Lemonade (LMND) trades at $46.91, showing modest daily gains of 0.17%. The stock faces bearish technical signals despite recent earnings beats, with revenue growth accelerating to 32% year-over-year in Q2 2026. The company demonstrates improving fundamentals with gross profit margin at 47.85% and narrowing losses, targeting EBITDA profitability by late 2026. Recent expansion into Alaska and Kentucky markets supports growth trajectory.

Lemonade presents a growth story with improving margins and AI-driven efficiency, but profitability remains elusive. The 33% upside to consensus price target of $67 offers potential reward, though persistent losses and competitive pressures pose significant risks. Investors must weigh the company's expansion momentum against its negative cash flow from operations and high valuation multiples.